The upside comes from a tiny revenue base, 2,000-plus deployed robots, and a second vertical in hospitals. I underwrite fast growth, but not a software-style
rerating: partner-controlled routing, services-heavy revenue, and high pricing elasticity should cap the valuation even if recurring mix and workflow depth improve.